Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Chemotherapy Combined With Immuno-targeted Drugs in Newly Diagnosed Adult Patients With Ph-negative B-cell Acute Lymphocytic Leukemia
NCT06387121Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin, blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2024; status: recruiting.
02
Drugs
inotuzumab ozogamicinblinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06387121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387121.